BackGalectin Therapeutics Overview

Galectin Therapeutics Long Term Debt

Track Galectin Therapeutics's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
↓ 100.00% YoYΔ $-120.46M vs prior year quarter

Peer trimmed avg / median

Loading

Galectin Therapeutics Long Term Debt History

Loading

Galectin Therapeutics vs. peers: Long Term Debt Comparison

Loading

Galectin Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Galectin Therapeutics (GALT) FAQ

As of the most recent data (June 2026), GALT shows a long-term debt of $0. That compares with $120M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GALT's long-term debt is now $0 (was $120M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Galectin Therapeutics is outperforming or lagging.

Tracking GALT's long-term debt over time shows whether Galectin Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $120M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Galectin Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Galectin Therapeutics's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.